Biswas Ahitagni, Chaudhari Pritee B, Sharma Punit, Singh Lavleen, Julka Pramod Kumar, Sethuraman Gomathy
Department of Radiotherapy and Oncology, All India Institute of Medical Sciences, New Delhi, India.
J Cancer Res Ther. 2013 Jul-Sep;9(3):500-3. doi: 10.4103/0973-1482.119358.
Bleomycin induced flagellate dermatitis is a rare and unique adverse effect. With the declining use of bleomycin, this complication is becoming increasingly infrequent in common clinical practice. We herein describe a case of a 22-year-old Indian male with Hodgkin's lymphoma, Ann Arbor stage IIBEX developing flagellate dermatitis following 1(st) cycle of chemotherapy with ABVD regimen. The diagnostic dilemma in the illustrative case underscores the importance of awareness and prompt identification and treatment of this dermatological toxicity in limiting morbidity in patients undergoing bleomycin based combination chemotherapy. In patients having severe rash, bleomycin should be expeditiously discontinued. Omission of bleomycin does not compromise the treatment outcome in the majority of patients with Hodgkin's lymphoma.
博来霉素诱发的鞭毛虫样皮炎是一种罕见且独特的不良反应。随着博来霉素使用的减少，这种并发症在普通临床实践中越来越不常见。我们在此描述一例22岁的印度男性霍奇金淋巴瘤患者，Ann Arbor分期为IIBEX，在接受ABVD方案化疗第1周期后发生了鞭毛虫样皮炎。该病例中的诊断困境凸显了在接受基于博来霉素的联合化疗患者中，认识、及时识别和治疗这种皮肤毒性对于降低发病率的重要性。对于有严重皮疹的患者，应迅速停用博来霉素。在大多数霍奇金淋巴瘤患者中，省略博来霉素并不影响治疗结果。
